Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 219
- Registration Number
- NCT01925768
- Locations
- 🇦🇺
Colin Bayliss Research and Teaching Unit, Victoria Park, Western Australia, Australia
🇺🇸Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States
🇨🇦Manitoba Clinic, Winnipeg, Manitoba, Canada
Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility
Phase 2
Terminated
- Conditions
- Asthma
- Interventions
- Biological: PlaceboBiological: Brodalumab
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 421
- Registration Number
- NCT01902290
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Procedure: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 725
- Registration Number
- NCT01901146
- Locations
- 🇬🇧
Research Site, Peterborough, England, United Kingdom
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
Phase 3
Completed
- Conditions
- Rheumatoid ArthritisPsoriatic Arthritis
- Interventions
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 77
- Registration Number
- NCT01901185
- Locations
- 🇺🇸
Research Site, Duncansville, Pennsylvania, United States
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
Phase 3
Completed
- Conditions
- Secondary HyperparathyroidismChronic Kidney Disease
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 683
- Registration Number
- NCT01896232
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Study of South African Dialysis Patients
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT01890577
- Locations
- 🇿🇦
Research Site, Roodepoort, South Africa
Study of Erenumab (AMG 334) in Women With Hot Flashes
Phase 1
Completed
- Conditions
- Vasomotor Symptoms; Hot Flashes
- Interventions
- Drug: PlaceboBiological: Erenumab
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 103
- Registration Number
- NCT01890109
- Locations
- 🇺🇸
Eugene Andruczyk, Philadelphia, Pennsylvania, United States
🇺🇸Research Site, Seattle, Washington, United States
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Phase 3
Completed
- Conditions
- Primary HypercholesterolemiaMixed Dyslipidemia
- Interventions
- Biological: Evolocumab AI/penBiological: Evolocumab AMD
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 164
- Registration Number
- NCT01879319
- Locations
- 🇨🇦
Research Site, Pointe-Claire, Quebec, Canada
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
Phase 4
Completed
- Conditions
- Rheumatoid ArthritisPlaque Psoriasis
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 217
- Registration Number
- NCT01875991
- Locations
- 🇨🇦
Research Site, Peterborough, Ontario, Canada
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
Phase 2
Completed
- Conditions
- Thyroid Associated OphthalmopathiesThyroid-Associated Ophthalmopathy
- Interventions
- Drug: normal saline
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 88
- Registration Number
- NCT01868997
- Locations
- 🇺🇸
Jules Stein Eye Institute at UCLA, Los Angeles, California, United States
🇮🇹Fondazione Ca' Granda Ospedale Policlinico Graves GO Center, Milan, Italy
🇮🇹University of Pisa, Azienda Ospedaliera, Pisa, Italy
© Copyright 2025. All Rights Reserved by MedPath